A5101609117- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Chemokine receptors and signaling
- Immune cells in cancer
- Hematopoietic Stem Cell Transplantation
- Glycosylation and Glycoproteins Research
- Advanced biosensing and bioanalysis techniques
- Cancer, Stress, Anesthesia, and Immune Response
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Biomedical Ethics and Regulation
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Immune responses and vaccinations
- T-cell and B-cell Immunology
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Biosimilars and Bioanalytical Methods
- Viral-associated cancers and disorders
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
Azienda Sanitaria Locale di Asti
2025
Research Institute Hospital 12 de Octubre
2024
Centro de Investigación Biomédica en Red de Cáncer
2021-2024
San Raffaele University of Rome
2023
Memorial Sloan Kettering Cancer Center
2023
Vita-Salute San Raffaele University
2023
Hospital Universitario 12 De Octubre
2021-2023
Consejo Superior de Investigaciones Científicas
2019-2022
Spanish National Cancer Research Centre
2019-2022
Centro Nacional de Biotecnología
2020-2022
A 21-year-old man presented to hospital with a two-month history of productive cough no other symptoms. Radiology revealed cavitating lesion in the left upper lobe for which variety diagnoses were considered. biopsy primary pulmonary Hodgkin’s lymphoma. Primary lymphoma is an uncommon initial presentation; lung lesions usually occur later course disease. Following diagnosis, patient began chemotherapy and full remission was achieved.
Background: Intra-vesical instillation of Bacille Calmette–Guérin (BCG), an attenuated strain Mycobacterium bovis, is effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% patients free relapse after three years. Because non-responder usually have bad prognosis, the early identification treatment failure crucial. We hypothesized that, if was taking place bladder, soluble factors would be released to urine many...
High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Guérin (BCG). Although most cancer patients respond well to BCG, there is no clinical parameter predictive treatment response, and when fails, the prognosis very poor. Further, a high percentage NMIBC BCG suffer unwanted effects that force them stop treatment. Thus, early identification in which will fail really important. Here,...
Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment mice carrying + T-ALL cell lines primary leukemias inhibits tumor growth and increases survival. The effects are specific synergize with chemotherapeutic agents increasing Furthermore, decreases size...
Background: HLA-E is highly expressed in several tumor cells, including metastatic and correlates with a poor prognosis. Its interaction the inhibitory receptor NKG2A, T lymphocytes NK enables cell escape. Although α-NKG2A antibodies have not shown positive preclinical clinical results as monotherapy so far, their combination other blocking has promise. Allogeneic CAR-NK cells recently emerged safer immunotherapy than CAR-T but efficacy could be limited due to high NKG2A expression. Aims:...
Abstract The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine algorithms, resulting improved response rates. Nevertheless, patients continue relapse the underlying mechanisms of resistance remain poorly understood. While Impaired death receptor signaling has reported mediate acute lymphoblastic leukemia, this mechanism yet...
Abstract High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Guérin (BCG). Although cancer patients respond well to BCG, important questions remain unanswered, including how identify at early stages non-responder and risk abandon the treatment. Here, we analysed cells released into urine longitudinally 3-7 days after BCG instillations. Mass cytometry (CyTOF) analyses revealed that most...